As of 2024-07-27, the EV/EBITDA ratio of Ocular Therapeutix Inc (OCUL) is -10.10. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCUL's latest enterprise value is 889.29 mil USD. OCUL's TTM EBITDA according to its financial statements is -88.02 mil USD. Dividing these 2 quantities gives us the above OCUL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 17.1x | 13.3x |
| Forward P/E multiples | 17.2x - 21.3x | 20.4x |
| Fair Price | (7.09) - (7.01) | (6.87) |
| Upside | -184.1% - -183.1% | -181.5% |
| Date | EV/EBITDA |
| 2024-07-26 | -10.10 |
| 2024-07-25 | -9.84 |
| 2024-07-24 | -9.19 |
| 2024-07-23 | -9.43 |
| 2024-07-22 | -9.10 |
| 2024-07-19 | -9.08 |
| 2024-07-18 | -8.91 |
| 2024-07-17 | -9.35 |
| 2024-07-16 | -10.05 |
| 2024-07-15 | -10.10 |
| 2024-07-12 | -9.57 |
| 2024-07-11 | -8.64 |
| 2024-07-10 | -7.87 |
| 2024-07-09 | -6.62 |
| 2024-07-08 | -6.99 |
| 2024-07-05 | -7.01 |
| 2024-07-03 | -7.04 |
| 2024-07-02 | -7.02 |
| 2024-07-01 | -6.99 |
| 2024-06-28 | -7.31 |
| 2024-06-27 | -7.16 |
| 2024-06-26 | -6.94 |
| 2024-06-25 | -6.81 |
| 2024-06-24 | -6.76 |
| 2024-06-21 | -6.27 |
| 2024-06-20 | -5.97 |
| 2024-06-18 | -4.93 |
| 2024-06-17 | -4.95 |
| 2024-06-14 | -5.39 |
| 2024-06-13 | -4.14 |
| 2024-06-12 | -3.94 |
| 2024-06-11 | -4.10 |
| 2024-06-10 | -4.03 |
| 2024-06-07 | -3.96 |
| 2024-06-06 | -4.42 |
| 2024-06-05 | -4.93 |
| 2024-06-04 | -4.60 |
| 2024-06-03 | -4.96 |
| 2024-05-31 | -5.30 |
| 2024-05-30 | -5.47 |
| 2024-05-29 | -5.60 |
| 2024-05-28 | -5.70 |
| 2024-05-24 | -5.47 |
| 2024-05-23 | -5.47 |
| 2024-05-22 | -5.83 |
| 2024-05-21 | -6.00 |
| 2024-05-20 | -6.34 |
| 2024-05-17 | -6.13 |
| 2024-05-16 | -6.30 |
| 2024-05-15 | -6.34 |